Elevance Health (0HG8)
London Exchange · UK · prices in USD · close of 19 Oct 2026
Key indicators
| Last close | USD 429.06 |
|---|---|
| 52-week range | 272.68 – 443.10 |
| Return, 1 month / 3 months | +5.1% / +11.8% |
| Return, 1 year / 3 years | +22.8% / +0.8% |
| Trend | Uptrend |
| RSI (14) | 67 |
| Volatility (1 year) | 32.9% |
| Worst drawdown (1 year) | -27.1% |
| Average daily value traded | 0.47M USD |
| Dividend yield | 1.6% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Elevance Health is a health benefits company based in the United States. It provides medical insurance and related benefits to individuals, employers and government programmes through its affiliated health plans, many of which carry the Blue Cross and Blue Shield names. The company also offers pharmacy benefits management, behavioural health services and care management through its subsidiaries, serving members across a broad range of commercial and public health plans.
Elevance Health trades under the code 0HG8 on the London Exchange in UK, with its price quoted in US dollars (USD). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Elevance Health (0HG8) trades on the London Exchange in UK. It last closed at USD 429.06 on 19 October 2026.
Its price-based Market X-Ray is 69 out of 100 (a fair price profile), ranking 624 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 22.8% and over the last three months it rose 11.8%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 86 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 16.9% | ||
| From 52-week high | -0.2% | ||
| Momentum | 79 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 11.8% | ||
| 6-month return | 37.1% | ||
| 12-month return, skipping the last month | 16.9% | ||
| Stability (higher is calmer) | 55 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 32.9% | ||
| Worst drawdown, 1 year (smaller is calmer) | -27.1% | ||
| Liquidity | 45 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.47M USD | ||
| Zero-volume days | 0.0% | ||
| Income | 69 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 1.6% | ||
| Years with dividends | 6 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
Weak spots
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | +2.3% |
|---|---|
| 1 month | +5.1% |
| 3 months | +11.8% |
| 6 months | +37.1% |
| 1 year | +22.8% |
| 3 years | +0.8% |
| 5 years | – |
Signals
| 50-day / 200-day average | 404.31 / 366.94 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | Yes |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 14.03 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 9 Sep 2026 | USD 1.7200 |
| 9 Jun 2026 | USD 1.7200 |
| 9 Mar 2026 | USD 1.7200 |
| 4 Dec 2025 | USD 1.7100 |
| 9 Sep 2025 | USD 1.7100 |
| 9 Jun 2025 | USD 1.7100 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.